Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.38 |
| ▸ | AXL | P30530 | 4/20 | 0.36 |
| ▸ | MERTK | Q12866 | 4/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19701784 | 0.78 | PIK3CD (0.48) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL19701787 | 0.77 | AXL (0.41) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL19701781 | 0.74 | PIK3CD (0.51) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL64684 | 0.72 | ACVRL1 (0.51) | ACVRL1AXLMERTKTYRO3ALDH1A1 | |
| SCHEMBL15826967 | 0.72 | AXL (0.54) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL19701785 | 0.72 | PIK3CD (0.46) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL12365553 | 0.72 | ALDH1A1 (0.43) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL66503 | 0.72 | ALDH1A1 (0.43) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL19701791 | 0.71 | ACVRL1 (0.44) | PIK3CDACVRL1AXLMERTKTYRO3 | |
| SCHEMBL7602863 | 0.71 | ACVRL1 (0.43) | PIK3CDACVRL1ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | PIK3CD 14/4885ACVRL1 2053/4885AXL 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.